Cabaletta Bio Gets Orphan Drug Designation for Potential Autoimmune Disease Treatment
By Ben Glickman
Cabaletta Bio announced it had received orphan drug designation from regulators for its potential treatment for an inflammatory muscle condition.
The company said Thursday that the Food and Drug Administration had granted the designation to CABA-201 in the treatment of idiopathic inflammatory myopathies, also called myositis.
Myositis is a category of autoimmune diseases characterized by inflammation and muscle weakness.
Cabaletta said CABA-201 is in development for a potential treatment of autoimmune diseases driven by B cells.
Orphan drug status is given by the FDA to drugs or biologics meant to treat rare diseases.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
February 01, 2024 16:59 ET (21:59 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
United States